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Abstract. Since systematic hematological studies on blood and bone marrow changes after treatment with 
15-Deoxyspergualin (DOS) are lacking, a quantitative assessment was performed fourteen or twenty eight days 
after intraperitoneal application of DOS to rats. Further observations done 7 and 14 days after discon-
tinuation of DOS administration allowed analysis of banc marrow regeneration. DOS induced lym-
phocytopenia, granUlocytopenia and anemia with a decrease of bone marrow cellularity due to suppression of 
cell maturation. The effect was dose-dependent and bone marrow as well as blood changes were observed in 
animals treated with doses from 0.5 to 10.0 mg/kg DOS. Within 14 days after termination of the treatment, 
rapid recovery with normalization of all hematological parameters was observed. In the light of our data, these 
hematological side effects may not be a major disadvantage, if DOS is used in doses below 2.5 mg/kg, and for 
a course of therapy which is limited to 7 to 14 days. 
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Introduction 
Deoxyspergualin (DOS), a substance composed of 
a guanidinic and a spergmidine moiety, was originally 
described as an antitumor agent6•13• Besides its documen-
ted activity against murine leukemias, it was shown to 
possess immunosuppressive properties3• DOS is present-
ly being investigated as a new immunosuppressive drug 
in several transplantation models. It was demonstrated 
that DOS effectively prolongs the survival of transplan-
ted kidneys8,1s, livers4, hearts 12 and other organs 7. 1l in 
doses ranging between 1.8 and 2.5 mg/kg given from day 
o to day 9 or 14 post-transplantation. DOS was also 
effectively used as a rescue drug for acute rejection of the 
lddney, in a dose of 2.4 mg/kg which could be reduced to 
0.6 mg/kg within 7 dayss. 
It has also been demonstrated that DOS given 
intraperitoneally in a dose of 2.5 mg/kg for 14 days 
induces specific immunological tolerance to the rat 
kidney allograft, as shown by indefinitely accepted 
donor type and normally rejected third party skin 
grafts14. Frozen tissue sections of surviving kidneys 
(treatment beginning on day + 1, + 2, or + 3) show 
a remarkable downregulation of MHC class 
I (MRC-OX18) antigens, but not class II (MRC-OX6) 
antigens on various kidney cells. When treatment 
begins as late as day + 5, DOS fails to inhibit 
upregulation of class I antigens as shown in rejected 
kidneys. DOS appears to reduce the expression of 
graft MHC class I antigens, i.e., of major target 
antigens, when given within the first days after 
transplantation. It also appears to interfere with 
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antigen presenting cells during the induction phase of 
allograft responses. Il-l production by splenic and 
peritoneal exudate macro phages, treated in vitro with 
DOS, is reduced significantly at lower DOS dosages 
(0.005-0.5 mg DOS/ml culture medium)14. 
However, some observations showed that DOS 
may also exhibit toxic effects. In experiments on dogs 
treated with DOS, a dose of 4.0 mg/kg for 10 days 
caused severe gastrointestinal disturbances and an-
orexia2.4.11. Leukopenia, anemia and reduction of 
mean spleen weight were observed in mice receiving 
5.0 mg/kg of DOS for 23 days or longer. Histologic 
examinations of spleen showed an atrophy of white 
pulp and a decrease of cells in red pulp 7. It was also 
found that DOS suppressed proliferation ad differen-
tiation of bone marrow cells when given in a dose of 
3.0 mg/kg for 4 dayslO. 
No systematic hematological studies on peri-
pheral blood and bone marrow changes during 
treatment with various doses of DOS have been 
published so far. Since future clinical application of 
this drug requires knowledge of its side effects, we 
performed a quantitative assessement of blood and 
bone marrow changes after a 14 or 28 day course of 
DOS applied intraperitoneally. Subsequent observa-
tion lasting 7 and 14 days after the end of DOS 
treatment allowed follow-up of bone marrow regene-
ration. 
Materials and Methods 
Immunosuppressive agent. lS-Deoxyspergualin 
produced by Nippon Kayaku Co. (Tokyo) was 
obtained from Behringwerke AG (Marburg). It was 
dissolved 111 sterile phosphate buffered saline 
(pH 7.2) 
Animals. Thirty nine male LEW (RTlI) rats, 
3 months old and weighing 250 - 300 g, bred in our 
Department, were used for the study. 
Rats were divided into the following experimental 
groups: 
Group I: Intraperitoneal injections of DOS in doses 
of 0.5,2.0,2.5, 5.0 and 10.0 mg/kg for 14 consecutive 
days (n = 5 per experiment). Group II: Intraperitone-
al injections of DOS in doses of 2.5, 5.0 and 
10.0 mg/kg for 14 consecutive days with a subsequent 
interval of 7 days before hematological examination 
(n = 3 per experiment). Group Ill: Intraperitoneal 
injections of DOS in doses of 2.5, 5.0 and 10.0 mg/kg 
for 14 consecutive days with a subsequent interval of 
14 days before hematological examination (n = 3 per 
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experiment). Group IV: Intraperitoneal injections 
of DOS for 28 consecutive days in a dose 2.5 mg/kg 
(n = 3 per experiment). Group V: Intraperitoneal 
injections of DOS for 28 consecutive days in a dose of 
2.5 mg/kg with a subsequent interval of 7 days before 
hematological examination (n = 3 per experiment). 
Group VI: Intraperitoneal injections of DOS for 28 
consecutive days in a dose of 2.5 mg/kg with a sub-
sequent interval of 14 days before hematologicaI 
examination (n = 3 per experiment). Control groups: 
Rats were injected only with PBS (n == 5 per ex-
periment). 
Hematoiogicai examinations. Blood and bone mar-
row were used for hematological investigation. Hemo-
globin, erythrocyte count, hematocrit, cell count, plate-
let count, blood and bone marrow smears were 
analysed. For estimation of bone marrow changes, 500 
cells were counted. Cells of granulocyte maturation 
line identified as myeloblasts, promyelocytes and mye-
locytes were summed up and interpreted as bone 
marrow proliferative pool of granulocytes (BM-PPG). 
Other cells of the granulocyte line: metamyelocytes, 
bands, and morphologically mature polymorphonuc-
lear granulocytes were summerically presented as bone 
marrow non-proliferative pool of granulocytes 
(BM-NPPG). All analyses were performed according 
to standard laboratory procedures. 
Statistical analyses were done according to the 
Student's t - test for "small samples". 
Results 
Leulwcytes 
Absolute counts of leukocytes in peripheral blood 
were significantly lower after 14 days of DOS treat-
ment than in the control group: 9806 ± 584 (p < 0.02) 
following 0.5 mg/kg and 3916±21SS (p < 0.01) fol-
lowing 10.0 mg/kg DOS versus 15075 ± 1694 in the 
control group. Seven days later, a regeneration phase 
was observed in that leukocyte counts increased to 
35733 ± 24135 following 2.5 mg/kg; 52516 ± 33 494 
following 5.0 mg/kg and 31833 ± 16064 following 
10.0 mg/kg (group I1). Two weeks after discontinua-
tion of DOS treatment the leukocyte values were 
normalized (group 1II). Similar findings were obser-
ved when a dose of 2.5 mg/kg DOS was given for 28 
days (group IV): the leukocyte count decreased from 
11 166±280 to 6733± 1270 (p < 0.01), and was nor-
malized two weeks after termination of treatment 
(group VI). 
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Lymphocytes 
The value of lymphocyte count in the control 
group was 10 856± 1099. The mean absolute count of 
lymphocytes in rats treated with 0.5 mg/kg of DOS 
was 7452± 137 (p < 0.05). In these rats the lym-
phocyte count exceeded the baseline level seven days 
after the last DOS injection and two weeks after 
cessation of treatment the count was normalized. In 
rats treated with higher DOS doses also a statistically 
significant reduction of lymphocyte counts was obser-
ved (group I). Again, seven days after the last DOS 
injection the lymphocyte counts exceeded that of 
controls (group Il). The highest values were observed 
in animals treated with 2.5 mg/kg DOS. Fourteen 
days after termination of DOS treatment the count 
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Fig.!. Absolute values of lymphocytes in peripheral blood of rals 
treated with various doses of DOS; 0, 2.5, 5.0 or 10.0 mg/kg. After 
14 days of DOS-treatment a significant reduction in Iymphocytc 
counts was observed (grollp I). A similar result was observed after 
28 days of DOS application (group IV). In the regeneration phase 
7 days after the last DOS injection the lymphocyte count exceeded 
that of the controls (groups Il and V). The highest counts were 
obtained in animals treated with 2.5 mg/kg. Two weeks after 
cessation of treatment, the count normalized (groups III and VI) 
was normalized only in rats injected with 5.0 mg/kg 
DOS (group Ill). In other rats the values were 
significantly lower than in the control group. The 
results are presented in Figure 1. DOS given in a dose 
of 2.5 mg/kg for 28 days (group IV) induced also 
a statistically significant reduction of lymphocytcs in 
peripheral blood (Fig. 1). 
Gl'anulocytes 
In rats treated 14 days with a dose of 0.5 mg/kg of 
DOS the mean count of granulocytes in peripheral 
blood decreased from 3167±372 to 1612±386 
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(p < 0). Rats treated with higher doses of DOS had 
lower counts of granulocytes in peripheral blood 
(group I). The results presented in Figure 2 show 
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Fig. 2. Absolute values or granulocytes 111 peripheral blood of rats 
treated for 14 days with various doses of DOS: 0, 0.5, 2.0, 5.0 or 
10.0 mg/kg. The results show that DOS treatment induced a sig-
nificant and dose-dependent reduction of granulocytc counts 
that DOS treatment induces significant reduction of 
granulocyte counts in peripheral blood in a do-
se-dependent manner. Seven days after the last DOS 
injection high numbers of granulocytes were observed 
(group Il). Fourteen days after cessation of treatment 
the count of granulocytes was normalized (Fig. 3). 
In groups IV, V and VI similar changes in granulocy-
le counts were observed as in rats treated with the 
same dose for 14 days. 
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Fig. 3. Time-dependeIlt changes in granulocyte COllnt in pCliphcral 
blood of rats treated with variolls doses of DOS; 0, 2.5, 5.0 or 
10.0 mglkg. DOS-therapy, continued for 14 (group I) or 28 days 
(group IV), induced a significant reduction of granulocyte count at all 
doses used in this study. Seven days after termination of treatment 
very high proliferation of granulocytes were observed (groups 11 and 
V). The grnnulocyte count normalized after 14 d,IYS (group 1JI and VI) 
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The femurs of rats treated 14 days with DOS 
showed bone marrow hypoceIlularity, especially in 
rats treated with 5.0 or 10.0 mg/kg of DOS. The 
quantitative bone marrow analyses demonstrated 
suppression of granulocyte maturation manifested by 
the increasing percentage of cells from BM-PPG. 
This even was strictly dose-related. Seven days after 
the last DOS injection cellularity of the femurs bone 
marrow significantly improved with concomitant in-
crease of granulopoetic cell maturation. It was mani-
fested by the increase of BM-NPPG 73.2% by 
2.5 mg/kg, 71.4% by 5.0 mg/kg and 69.1 % by 
10.0 mg/kg versus 61.3% in the control group. Four-
teen days after termination of treatment, the bone 
marrow granulopoietic system was almost normal 
(Fig. 4). The more prolonged treatment with DOS 
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Fig. 4. Percentage values of granulocyte precursors in the bon~ 
marrow proliferative pool of granulocytes in rats treated with 
various doses of DOS: 0, 2.5, 5.0 Of 10.0 mg/kg. DOS was applied 
for either 14 (group J) or 28 (group IV) consecutive days. After that 
time an increased percentage of granulocyte precursors was obser-
ved in bone marrow (groups II and V). Seven days after ter-
mination of DOS treatment the percentftge of granulocyte precur-
sors decreased below the normal value. These values normalized 
after 14 days (group III and VI) 
in a dose of 2.5 mg/kg (groups IV, V and VI) induced 
similar changes, but the normalization of granulopoi-
esis lasted significan~ly longer. 
Red blood cells (RBC) 
The mean erythrocyte count in the control group 
was 8.776.000 ± 489.000. The absolute values of eryth-
rocytes in rats treated with DOS for 14 days were 
within the normal range (group I). A decrease of 
erythrocyte counts was observed in animals treated 
for 28 days with a dose of 2.5 mg/kg (group IV). 
These decreased values significantly improved but did 
not return to normal level after 14 days (group VI) 
(Fig. 5). 
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Fig. 5. Absolute values of erythrocytes in peripheral blood of rats 
treated with various doses of DOS 0, 2.5, 5.0 or 10.0 mg/kg. After 
14 days of DOS therapy the reduction of erythrocyte count was 
observed only in the group of rats that had been treated with 
10.0 mg/kg. Animals treated for 28 days showed also reduced 
erythrocyte count, althoguh the dose was only 2.5 mg/kg (group 
IV). Seven and fourteen days after termination of treatment the 
count did not yet normalize in those groups (groups V and VI), but 
significantly improved (group VI vs. IV) 
OOS treatment induced a significant reduction of 
cells of the erythroblastic system of bone marrow. 111 
rats treated with 2.5 mg/kg percentage value of cryth-
roblasts was observed 1.6 ± 1.1 versus 22.0 ± 7.8 in 
controls. However, this was recovered after the ter-
mination of treatment. Seven days after the last DOS 
injection, a significant increase of erythroblasts in 
bone marrow and the appearance of single nucleared 
red blood cells in peripheral blood were observed. 
But the mean values were lower than in controls. In 
groups IV, V and VI a similar reduction of erythrob-
last percentage values was observed. However, nOf-
malization of erythroblast values in bone marrow 
was found two weeks after the end of DOS treatment. 
T hromboc ytes 
The value of thrombocyte count in the control 
group was 697.oo0± 19.200. After 14 days of DOS 
treatment platelet counts were lower than those of the 
control group: 434.000± 130.000, 370.000±70.000, 
208.000 ± 19.000 and 170.000 ± 98.000 in rats receiving 
doses of 0.5, 2.5, 5.0, 10.0 mg/kg DOS respectively. Seven 
days after the last DOS injection the platelet counts were 
significantly higher a.nd reached the normal limit 
(565.000 ± 186.000 in animals treated with 10.0 mg/kg). 
In rats treated with a dose of 2.5 mg/kg for 28 days 
nonnal value of platelet count was observed after the end 
of injections and during the recovery phase, 
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Hemoglobin (Hb) 
The mean Hb level in the control group was 
15.8±0.5 g/dl. In rats treated with small doses of 
DOS, 0.5 and 2.5 mgjkg for 14 days, the mean Hb 
level was significantly decreased: 13.8 ± 0.3 and 
13.8 ± 0.1 (p < 0.01) respectively. In rats injected with 
5.0 and 10.0 mgjkg these values were nearly within 
normal range: 14.7 ± 1.4 and 14.7 ± 0.7 respectively. 
However, a decrease of Rb level was observed 7 days 
after termination of treatment 11.2±3.2 and 
12.7 ± 0.6 (p < 0.01) respectively. Normalization of 
Hb level was detected 14 days after the last DOS 
injection. Similar reduction of Hb level was observed 
in rats treated for 28 days with 2.5 mg/kg DOS. 
Hematocrit (Ht) and body weight 
The mean Ht value in the control group was 
0.448 ± 0.006. Ht values were significantly reduced on 
day 14 in rats treated with 0.5 and 2.5 mg/kg: 
0.423±0.11 and 0.418±0.008 (p < 0.001). In rats 
treated with 5.0 and 10.0 mg/kg Ht and Hb values 
were within normal limits, however, a reduction of 
body weight connected with diarrhoea was observed: 
166± 5 g (p < 0.01) in animals treated with 
10.0 mg/kg versus 255 ±25 g in controls. Seven days 
after termination of treatment, Ht values were sig-
nificantly lower in all groups: 0.364 ±0.028 (p < 0.02), 
0.337 ± 0.078 (p < 0.05), 0.375 ± 0.017 (p < 0.01) in 
rats receiving doses of 2.5, 5.0 and 10.0 mg/kg DOS 
respectively (group Il). Two weeks after termination 
of DOS, normalization of Ht and body weight were 
observed (group III). In rats treated for 28 days with 
2.5 mg/kg DOS decrease of Ht was more prominent 
at the end of treatment up to seven days later 
(O.336±0.017 and 0.367±0.074). The value normali-
zed two weeks after termination of DOS injections. 
During this mode of treatment no body weight 
changes were observed (groups IV, V and VI). 
Discussion 
Experimental studies in rats and dogs showed 
that although DOS is an effective drug for the 
prolongation of graft survival, it has a negative 
influence on cell counts in peripheral blood. These 
observations were confirmed lately in clinical studies 
where renal graft patients had received DOS as 
a rescue drug l . The reduction of white blood cells 
other than lymphocytes was the most notable adverse 
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reaction. Moreover, reduction of red blood cells and 
platelets was observed. 
The current studies were undertaken to inves-
tigate the changes in peripheral blood ce11 counts as 
well as cel1 maturation in bone marrow in rats 
receiving differet doses of DOS intra peritoneally. 
Our studies confirmed earlier observations of granu-
locytopenia during DOS treatment. However, in 
contrary to observations made by AMEMIYA et aLl 
and by NISHIMURA and TOKUNAGA 10 who injected 
mice with a dose of 3.0 mg/kg DOS and described 
that peripheral lymphocytes underwent only minor 
changes during and after treatment, we have observed 
a significant reduction of absolute numbers of lym-
phocytes. This effect was seen even in rats treated 
with a dose as low as 0.5 mg/kg. This difference in 
lymphocyte reduction may depend on longer periods 
of treatment in our experimental design. We have 
injected animals for fourteen days, whereas AMEMIYA 
et aJ.l and NISHIMURA and TOKUNAGAlo for five and 
four to nine days, respectively. 
Similarly to AMEMIYA et al.\ we observed a reduc-
tion of platelet and red blood cell counts. It appears 
probable that DOS causes thrombocytopenia by 
suppressing platelet production through a toxic ef-
fects on the megakarocytes. The cause of anemia, 
however, could be more complex. It is well known 
that some anemic crises may be related to drug 
toxicity, but gastroenterological side effects of the 
DOS manifested as diarrhea may induce protein 
malnutrition and deficiences of folic acid, ascorbinic 
acid and riboflavin which have also been implicated 
in the etiology of anemic crises. Taking into cosidera-
tion that changes in the erythroblastic system ap-
peared very early in DOS treatment and that the 
changes were reversible shortly after discontinuation 
of this drug it is more likely that a toxic drug effect, 
rather than malnutrition, was the most important 
factor for induction of anemia. 
Repeated intraperitoneal injections of DOS resul-
ted in a depressed granulopoietic and erythropoietic 
function of bone marrow. This effect was dose-depen-
dent. DOS did not decrease cell proliferation, but 
suppressed the maturation of granulocyte precursors 
of the bone marrow proliferative pool of granulocy-
tes. The percentage of immature granulocyte precur-
sor was increased. The consequence of depressed 
granulocyte maturation was reduced percentage of 
mature cells in bone marrow with its hypocelluiarity. 
Our results confirmed those of NISHlMURA and 
TOKUNAGA 10 that DOS blocked maturation of bone 
marrow cells, whereas functionally responsive stem 
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cells remained in bone marrow. The discontinuation 
of DOS treatment led quickly to recovery of bone 
marrow cellularity and normalization of the granulo-
poietic system. 
The erythropoietic system appears to be par-
ticularly sensitive to DOS, as the percentage values of 
erythroblastic cells decreased significantly even in rats 
treated with small doses of DOS. The DOS-depen-
dent reduction of erythrocyte numbers in peripheral 
blood in rats treated with high doses was masked by 
diarrhea, body weight loss and hemoconcentration. 
The most intensive anemia was seen seven days after 
termination of treatment. At this time the diarrhea 
disappeared and the body weight increased. As a con-
sequence of body hydration, the Ht values decreased. 
After termination of treatment a sharp increase of 
erythroblast number in the bone marrow was obser-
ved and the animals recovered very rapidly from 
anemia. These observations allow us to suggest that 
DOS has only minor side effects at doses below 
2.5 mg/kg used not longer than 7 -14 days. 
The results of our study suggest dose-dependent 
drug-induced granUlocytopenia and anemia, which 
are probably due to DOS interference with cell 
proliferation. The drug action is not selective and is 
likely to involve pluripotent cells. However, the 
hematological recovery commences already a few 
days following cessation of drug treatment. The cell 
counts rise rapidly to levels exceeding the normal 
range. 
These effects are minor in doses below 2.5 mg/kg 
applied not longer than for fourteen days. Termina-
tion of treatment leads to normalization of most 
changes within two weeks. 
There is little published data on the mechanisms 
of these reversible toxic effects of DOS. It was shown 
that DOS requires metabolic activation to express its 
cytotoxic effects and it was suggested that its active 
products are aldehydesu . Studies performed in dogs, 
in which a toxic cystitis was observed (a typical effect 
of aldehyde toxicity), may support this suggestion. 
Spergualin which is a polyamine antibiotic, isolated 
from cultures of Bacillus laterospm'us, may be trans-
formed to toxic aldehydes by oxidase. KUNIMOTO et 
a1. 9 demonstrated that an anti-proliferative influence 
of spergualin in vitro depended on the oxidase con-
centration in the medium. 
Further studies are required to clarify the mecha-
nism of DOS toxicity. They are especially needed in 
respect of future use in human organ transplantation. 
Our studies show that hematological side effects may 
developed after DOS therapy and that it is neces-
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sary to collect observations in patients treated with 
DOS, to estimate the level of toxicity and to control 
whether this effect is also reversible. 
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